Drugs / G305
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02387125 | Feb 2015 → Mar 2019 | melanoma, non-small cell lung carcinoma, ovarian cancer, sarcoma | Immune Design | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02609984 | Apr 2015 → Feb 2019 | myxoid/round cell liposarcoma, synovial sarcoma | Immune Design | Terminated | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03520959 | Sep → Nov 2018 | synovial sarcoma | Immune Design | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G305 | “and G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion” NCT02609984 ↗2“where intradermal LV305 is administered sequentially with intramuscular G305 over three months” NCT02387125 ↗ |
| Modality | Protein / enzyme biologic | “G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion” NCT02609984 ↗ |
| Route | Intramuscular | “G305 administered intramuscularly (IM)” NCT02609984 ↗ |